|Systematic (IUPAC) name|
|Mol. mass||616.26 g/mol|
|(what is this?)|
Casopitant (trade names Rezonic (US), Zunrisa (EU)) is an neurokinin 1 (NK1) receptor antagonist undergoing research for the treatment of chemotherapy-induced nausea and vomiting (CINV). It is currently under development by GlaxoSmithKline (GSK).
In July 2008, the company filed a marketing authorisation application with the European Medicines Agency. The application was withdrawn in September 2009 because GSK decided that further safety assessment was necessary.
- Lohr L (2008). "Chemotherapy-induced nausea and vomiting". Cancer J 14 (2): 85–93. doi:10.1097/PPO.0b013e31816a0f07. PMID 18391612.
- "GlaxoSmithKline withdraws its marketing authorisation application for Zunrisa". London: EMEA. 13 October 2009. Retrieved 21 December 2009.
|This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.|
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|